NUTEX HEALTH INC (NUTX) Earnings History & Surprises

NASDAQ:NUTX • US67079U3068

90.49 USD
-6.29 (-6.5%)
Last: Mar 11, 2026, 08:16 PM

Past quarterly earnings results for NUTEX HEALTH INC (NUTX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).

Earnings Snapshot

Next Earnings Date

Upcoming
Release DateMay 11, 2026
PeriodQ1 / 2026
EPS Estimate$5.23
Revenue Estimate247.03M

Last Reported

Most Recent
Release DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported$1.61
EPS Surprise -76.92%
Revenue Surprise -42.54%

Beat Rate

Last 8 Quarters
44%
EPS and Revenuebeats vs estimates

Quarterly Earnings Results

EPS & Revenue History (USD)

Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.

QuarterEPSEPS EstEPS SurpriseEPS Q2QRevenueRevenue EstRevenue SurpriseRevenue Q2Q
Q4 2025 1.61 6.98 -76.92% -85.52% 151.679M 263.99M -42.54% -41.12%
Q3 2025 7.76 1.11 597.97% 551.16% 267.804M 218.09M 22.80% 239.87%
Q2 2025 -2.95 -2.93 -0.77% -4,114.29% 243.985M 226.37M 7.78% 220.69%
Q1 2025 2.56 2.34 9.60% 526.67% 211.789M 120.05M 76.42% 213.98%
Q4 2024 11.12 -0.13 8,939.67% - 257.618M 82.748M 211.33% 269.77%
Q3 2024 -1.72 -0.24 -602.61% -14.67% 78.795M 74.689M 5.50% 25.62%
Q2 2024 -0.07 -0.30 76.34% 95.33% 76.082M 69.564M 9.37% 29.12%
Q1 2024 -0.60 0.00 - 60.00% 67.454M 66.096M 2.05% 19.75%
Q4 2023 0.00 0.00 - 100.00% 69.669M 72.828M -4.34% 29.68%
Q3 2023 -1.50 -0.77 -96.08% - 62.723M 64.515M -2.78% 120.89%
Q2 2023 -1.50 -0.77 -96.08% -4,900.00% 58.924M 63.291M -6.90% 1.51%
Q1 2023 -1.50 -2.30 34.64% - 56.329M 57.171M -1.47% -28.81%
Q4 2022 -3.00 -2.30 -30.72% - 53.724M 50.924M 5.50% 807.50%
Q3 2022 - - 28.395M - 409.88%
Q2 2022 -0.03 - - 58.048M - 997.11%
Q1 2022 - - 79.127M - 3,828.85%
Q4 2021 - - 5.92M - 1,410.20%
Q3 2021 - - 5.569M - 1,491.14%
Q2 2021 - - 5.291M - 1,296.04%
Q1 2021 - - 2.014M - 332.19%
Q4 2020 - - 392K - -
Q3 2020 - - 350K - -
Q2 2020 - - 379K - -
Q1 2020 - - 466K - -

Notes

  • EPS and Revenue values are non-GAAP when available, otherwise GAAP.
  • Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
  • Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
  • Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.

Earnings Q2Q Performance Trends

EPS Historical Q2Q growth and Acceleration

NUTX EPS Q2Q GrowthNUTX EPS Q2Q GrowthEPS Q2Q Growth Q2/23 Q4/23 Q1/24 Q2/24 Q3/24 Q1/25 Q2/25 Q3/25 Q4/25 Q1/26 Q2/26 Q3/26 Q4/26 0 -1K -2K -3K -4K

Revenue Historical Q2Q growth and Acceleration

NUTX Revenue Q2Q GrowthNUTX Revenue Q2Q GrowthRevenue Q2Q Growth Q1/21 Q3/21 Q1/22 Q3/22 Q1/23 Q3/23 Q1/24 Q3/24 Q1/25 Q3/25 Q1/26 Q3/26 0 1K 2K 3K

Surprise distribution (Last 4 Quarters)

EPS beat statistics

EPS beat (4)
3
Average EPS beat (4)
2,386.61%
Max EPS beat (4)
8,939.67%
Min EPS beat (4)
-0.77%

Revenue beat statistics

Revenue beat (4)
4
Average Revenue beat (4)
79.58%
Max Revenue beat (4)
211.33%
Min Revenue beat (4)
7.78%

Analysis

In the last 4 quarters, NUTX has beaten EPS estimates in 3 out of 4 releases
NUTX has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, NUTX has beaten the EPS estimates by 2386.6% on average.
In the last 4 quarters, NUTX has beaten the revenue estimates by 79.6% on average.
→ Find peers who consistently beat earnings by at least 10% in the last 4 quarters

NUTEX HEALTH INC / NUTX Earnings FAQ

When did NUTEX HEALTH INC (NUTX) report earnings last quarter?

NUTEX HEALTH INC (NUTX) last reported earnings on 3/5/2026.


Can you provide information on whether NUTEX HEALTH INC beat earnings estimates in the last quarter?

NUTEX HEALTH INC (NUTX) missed EPS estimates and missed revenue estimates in the most recent quarter.


What percentage of the time does NUTX stock beat earnings estimates?

In the last 4 quarters, NUTEX HEALTH INC (NUTX) has beaten EPS estimates in 3 out of 4 releases.